CAR	chimeric antigen receptor
HSCT	haematopoietic stem cell transplantation
FDA	Food and Drug Administration
R/R	relapsed/refractory
B-ALL	B cell acute lymphoblastic leukaemia
B-NHL	B cell non-Hodgkin lymphoma
MM	multipl e myeloma
TME	tumour microenvironment
scFv	single-chain fragment variable
AICD	activationinduced cell death
MDSCs	myeloid-derived suppressor cells
TAMs	tumourassociated macrophages
Tregs	regulatory T cells
IDO	indoleamine 2,3-dioxygenase
BCMA	B cell maturation antigen
GS	γ-secretase
TRAIL	tumour necrosis factor-related apoptosis-inducing ligand
Bcl-2	B cell lymphoma-2
IAPs	inhibitor of apoptosis family of proteins
OS	overall survival
PD	progressive disease
HR	hazard ratio
CI	confidence interval
Cy	cyclophosphamide
Flu	fludarabine
BSA	body surface area
AUC	area under the curve
LFS	leukaemia-free survival
HL	Hodgkin lymphoma
BTK	Bruton’s tyrosine kinase
allo-HSCT	allogeneic haematological stem cell transplantation
CLL	chronic lymphocytic leukaemia
CR	complete remission
MRD	minimal residual disease
CRS	cytokine release syndrome
GVHD	graft-versus-host disease
DLBCL	diffuse large B cell lymphoma
ORR	overall response rate
ASCT	autologous haematopoietic stem cell transplantation
HDT-ASCT	high-dose chemotherapy and ASCT
BEAM	carmustine etoposide cytarabine and melphalan
PFS	progression-free survival
G-CSF	granulocyte colony-stimulating factor
BUCY	busulfan and cyclophosphamide
VGPR	very good partial remission
PR	partial remission
MCL	mantle cell lymphoma
ITK	IL-2-induced tyrosine kinase
ICANS	immune effector cell-associated neurotoxicity syndrome
PBMCs	peripheral blood mononuclear cells
Th	T helper
mAb	monoclonal antibody
LBCL	large B cell lymphoma
ADC	antibody–drug conjugate
Bregs	regulatory B cells
PD-1	programmed-cell-death-1
PD-L1	programmed-cell-deathligand-1
PI3K	phosphatidylinositol-3-kinase
Tcm	central memory T cell
Tn	naïve T cell
GSI	g-secretase inhibitor
ATRA	all-trans retinoic acid
IL	interleukin
Tscm	T memory stem cell
TGF-β	transforming growth factor-β
COX-2	cyclooxygenase-2
GM-CSF	granulocyte-macrophage colonystimulating factor
DAC	decitabine
DNMTi	DNA methyltransferase inhibitor
AZA	azacitidine
HDACi	histone deacetylase inhibitor
BET	bromodomain and extraterminal domain
cBAF	canonical BRG1/BRMassociated factor
BD98	BRD-K9864598
GSK-3β	glycogen synthase kinase-3β
CTLA-4	cytotoxic T lymphocyte-associated antigen-4
CRi	complete remission with incomplete count recovery
mCD19	murine CD19
hCD22	humanized CD22
TIGIT	T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain